Quick Answer
Phathom Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $129.97 million for the year ending 2025.
- Phathom Pharmaceuticals, Inc. showed a decrease of -56.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Phathom Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $74.48 million | Q1 2020: $256.67 million | Q2 2020: $247.27 million | Q3 2020: $226.36 million | Q1 2021: $237.97 million | Q2 2021: $209.67 million | Q3 2021: $224.62 million | Q1 2022: $138.09 million | Q2 2022: $207.39 million | Q3 2022: $196.84 million | Q1 2023: $129.57 million | Q2 2023: $248.85 million | Q3 2023: $213.68 million | Q1 2024: $322.23 million | Q2 2024: $276.24 million | Q3 2024: $334.68 million | Q1 2025: $212.32 million | Q2 2025: $149.57 million | Q3 2025: $135.16 million.
- Over the full 8 years of available data (2018 to 2025), Phathom Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 14,686.3%.
- Historical annual values: Fiscal year 2025: $129.97 million | Fiscal year 2024: $297.26 million | Fiscal year 2023: $381.39 million | Fiscal year 2022: $155.39 million | Fiscal year 2021: $183.26 million | Fiscal year 2020: $287.50 million | Fiscal year 2019: $243.77 million | Fiscal year 2018: $879.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: